3. Gerhard Naude CEO Go Life International Limited
Dr. Wolfgang Schoenfeld CEO Go Life Global
Greg Gilbert Research & Business Development
Dr. Lana Du Plessis Research & Development
Marthinus Wolmarans CFO Go Life International
KEY TEAM MEMBERS
Extensive experience in management of people and companies
Strong financial and operational background
Scientific excellence
4.
Go Life International - a class leading multinational, nutraceutical
and cosmeceutical company
According to Frost & Sullivan (leading market research and
analyst company) – the nutraceutical and cosmeceutical
industry is expected to reach USD 500 billion in 2018
Our products are formulated using unique patent protected
technology and know-how
Go Life has the required skills and experience to significantly
increase its share of the domestic market, and launch / establish
its product range in key international markets
Go Life has experienced exponential sales growth since 2005
EXECUTIVE SUMMARY
5. EXECUTIVE SUMMARY (continued)
Our fully integrated business model encompasses in-house
research, product development, superior quality products with
global appeal
Go Life listed on the Stock Exchange of Mauritius in 2011
Go Life has received approval from the Advisory Committee of the
Johannesburg Stock Exchange for listing on the AltX by Q3 of 2015
6. MILESTONES
2011
Listing of Go Life on the Stock Exchange of Mauritius
2008
Gerhard Naudé - Establishment of Go Life Health Products
rebranding, and market expansion
2006
Robert Matzner – Founder of Gotha - exclusive distribution of
Gotha products
2005
Dr. Henry Davis – Inventor of Gotha products –widely
acknowledged efficacy - unique patented products
2011
Dr Wolfgang Schoenfeld founded Solmic Research based
on a unique technology and range of products –
marketed through Sodocos GmbH
7. MILESTONES (continued)
2015
Approval for Listing of Go Life on AltX of the
Johannesburg Stock Exchange
2014
Negotiations with German counterparts in the nutraceutical field
2013
Signed subscription in shares with a German AG
Start of listing process on Frankfurt Stock Exchange
October-December 2014
Formation of new Go Life International Group
9. THE BUSINESS
Health Sector
Life Sciences focus on Nutraceuticals and Cosmeceuticals
Fully integrated company covering research, development,
manufacturing, marketing of high quality health products
IP : strong patent portfolio and proprietary know-how
Medical care and frail centres
Operational Sites: South Africa, EU and USA
10. MARKETS: Nutraceuticals Cosmeceuticals
More than food and cosmetics,
natural extracts, vitamins, co-factors, essential oils
Efficacy closer to pharmaceuticals, safety closer or identical to food
and cosmetics
Provide health and medicinal benefits including prevention and
treatment of diseases
Increase life expectancy and quality of life -
a daily necessity for an active and healthy lifestyle
Scientific knowledge and proven data and processes necessary for
product efficacy, marketing success and regulatory approvals
Combined market size to reach 500 Bill USD by 2018
11. Nutraceuticals
Compound annual growth of 7%
Cosmeceutical market increasing annually by approx. 8%
Fredonia Marketing Research 2011
Cosmetics
Growth of cosmeceuticals will outperform growth of cosmetics
MARKETS
Market for health supporting products growing significantly
faster than Global GDP
Phenomenon the result of increased health awareness, aging
population and rapid expansion of global middle class
12. TECHNOLOGY BACKGROUND
Go Life’s success is founded on:
Patented technologies, products, ingredients and proprietary
formulas
Extensive knowledge and exceptional product innovation
Established marketing routes and distribution networks
Key proprietary advantage – technology to dramatically increase
Bioavailability and absorption of compounds
13. TECHNOLOGY BACKGROUND (continued)
Without water, there is NO life:
Evolution has optimized the uptake of substances
into the body based on water soluble ingredients
Fat soluble ingredients, e.g. vitamins A, D, E, Cofactor Q10 and
essential Omega 3-fatty acids are poorly absorbed by the
intestinal tract: uptake lower than 10% ; 90% excreted
Low bioavailability = High dosing required, thus increase in costs,
taste problems and gastrointestinal issues
Many products overdosed, poor tasting with little efficacy
Many natural ingredients and extracts are unstable and
insoluble
14. INCREASING BIOAVAILABILITY
Making active ingredients water soluble
e.g. Vitamin A, D, E, CoQ10, resins, extracts
Mimicking the natural process of food absorption based on bile salt
mediated uptake (“Micellation”)
More efficient and versatile than competitor technologies
15. THE CHALLENGE EXAMPLE - Vitamin D
Winter depression low vitamin D levels
due to low sun exposure
Vitamin D more than a bone hormone, 80% of
all cells react to Vitamin D – yet 70%
of entire population Vitamin D
deficient
Host defence enhancement of natural
resistance to infection
Cardiac function enhancement of heart function
Cancer clear evidence of activity in certain
cancers e.g. breast cancer
16. OUR CORE ASSETS
Know-How and IP
- patent portfolio covering Go Life’s technology
- internal know-how on technologies and unique formulations
Strong expertise in research and development
- understanding biochemistry and medicine
- understanding the mechanism of action between ingredients
- expertise in preclinical and clinical trials
- strong link to scientific community
Extensive experience in manufacturing
- in-house preparation of extracts
- production of intermediates and final products
17. OUR ASSETS
Close contact with Customers and the Medical Community
(Pharmacists, Therapists, Physicians, Health Care Workers)
Thorough understanding of regulatory environment
in EU, US and SA
- in SA all products are registered with MCC
Extensive experience in medical product marketing
(flyers, background literature, brochures etc.)
18.
19. THE FINANCIALS
The basis of our projections
Products currently marketed in SA and EU
Experience in the US market
Production and product costs clearly established
Cost of company acquisitions are fixed
Company overhead-structure costs in SA,
EU and US in-line with historical cost
Setting up solid base for future projections
20. THE FINANCIALS (continued)
Extrapolation of existing market values
Addressing individual marketing channels
e.g. US: direct marketing; SA: major retail chains
Addressing initial significant marketing costs
Addressing continuous development of products
Conservative growth estimates
Testing sensitivity of the model
Identifying key parameters and go´s and no go´s for EBIT/Cashflow P/L
25. RATIONALE FOR LISTING
Global investors would prefer to invest into a more liquid and
wider recognised Stock Exchange like the AltX of the
Johannesburg Stock Exchange
South African investors are precluded from investing in
current offshore structure
The new dual listing will accommodate South African and
International investors
26. PROSPECTS
Existing registration at local authorities will pave the way
for marketing new products and entering new markets
Continous research and development of products will be
boosted by existing and newly established laboratories in
Germany and South Africa
Marketing spend i.r.o the globalisation of the existing brands
will provide benefits across the group
Production will be decentralised – close to individual distribution
and marketing channels
Close interaction beween the sites will ensure highest
product quality and global sustainability
